Literature DB >> 24459458

Value of anti-VEGF treatment in choroidal neovascularization associated with autosomal recessive bestrophinopathy.

Savitha Madhusudhan1, Ahsen Hussain1, Jayashree N Sahni1.   

Abstract

A 26-year-old white woman presented with a 1-year history of reduced vision in both eyes, bilateral yellowish deposits in the central macula, and pale yellow retinal flecks extending to midretinal periphery. Choroidal neovascularization (CNV) was confirmed in her left eye. On optical coherence tomography, both eyes showed diffuse intraretinal cystic spaces, thickening and separation of the photoreceptor layer from the retinal pigment epithelium (RPE), subretinal fluid, and focal thickening at the level of the RPE at the fovea. A diagnosis of autosomal recessive bestrophinopathy was confirmed by electrodiagnostic and molecular genetics testing. The CNV responded well to intravitreal ranibizumab therapy, and visual acuity in the left eye improved and stabilized; however, retinoschisis due to fluctuations in intraretinal fluid persisted. This case highlights the fact that current optical coherence tomography-driven protocols used widely to treat neovascular age-related macular degeneration may not be appropriate for CNV associated with other retinal diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24459458      PMCID: PMC3899805          DOI: 10.5693/djo.02.2013.09.001

Source DB:  PubMed          Journal:  Digit J Ophthalmol        ISSN: 1542-8958


  7 in total

Review 1.  Bestrophins and retinopathies.

Authors:  Qinghuan Xiao; H Criss Hartzell; Kuai Yu
Journal:  Pflugers Arch       Date:  2010-03-28       Impact factor: 3.657

2.  How the comparison of age-related macular degeneration treatments trial results will impact clinical care.

Authors:  Janet Davis; Timothy W Olsen; Michael Stewart; Paul Sternberg
Journal:  Am J Ophthalmol       Date:  2011-10       Impact factor: 5.258

3.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

Authors:  Anne E Fung; Geeta A Lalwani; Philip J Rosenfeld; Sander R Dubovy; Stephan Michels; William J Feuer; Carmen A Puliafito; Janet L Davis; Harry W Flynn; Maria Esquiabro
Journal:  Am J Ophthalmol       Date:  2007-04       Impact factor: 5.258

4.  Autosomal recessive best vitelliform macular dystrophy: report of a family and management of early-onset neovascular complications.

Authors:  Alessandro Iannaccone; Natalie C Kerr; Tyson R Kinnick; Jorge I Calzada; Edwin M Stone
Journal:  Arch Ophthalmol       Date:  2011-02

5.  Detailed analysis of retinal function and morphology in a patient with autosomal recessive bestrophinopathy (ARB).

Authors:  Christina Gerth; Robert J Zawadzki; John S Werner; Elise Héon
Journal:  Doc Ophthalmol       Date:  2008-11-05       Impact factor: 2.379

6.  Biallelic mutation of BEST1 causes a distinct retinopathy in humans.

Authors:  Rosemary Burgess; Ian D Millar; Bart P Leroy; Jill E Urquhart; Ian M Fearon; Elfrida De Baere; Peter D Brown; Anthony G Robson; Genevieve A Wright; Philippe Kestelyn; Graham E Holder; Andrew R Webster; Forbes D C Manson; Graeme C M Black
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

7.  Ca2+ channels in retinal pigment epithelial cells regulate vascular endothelial growth factor secretion rates in health and disease.

Authors:  Rita Rosenthal; Heinrich Heimann; Hansjürgen Agostini; Gottfried Martin; Lutz Lothar Hansen; Olaf Strauss
Journal:  Mol Vis       Date:  2007-03-27       Impact factor: 2.367

  7 in total
  2 in total

1.  Ten-Year Follow-Up after Bilateral Submacular Neovascular Membrane Removal in a Case of Autosomal Recessive Bestrophinopathy.

Authors:  Carlos A Moreira; Carlos A Moreira-Neto; Mario Junqueira Nobrega; Eduardo Cunha de Souza
Journal:  Case Rep Ophthalmol       Date:  2017-04-24

2.  Diffuse Outer Layer Opacification: A Novel Finding in Patients With Autosomal Recessive Bestrophinopathy.

Authors:  Emily Witsberger; Alan Marmorstein; Jose Pulido
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2019 Nov-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.